How to predict severe influenza in hospitalized patients
The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the… read more.
The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the… read more.
Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening… read more.
KU Leuven researchers have identified the biological mechanism that explains why some people experience abdominal pain when they eat certain foods. The finding paves the way for more… read more.
Asthma afflicts more than 300 million people worldwide. The most severe manifestation, known as non-Th2, or non-atopic childhood asthma, represents the majority of the cases, greater than 85%,… read more.
An influenza vaccine that is made of nanoparticles and administered through the nose enhances the body’s immune response to influenza virus infection and offers broad protection against different… read more.
AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy… read more.
Wheezing, coughing that doesn’t stop, a pale and sweaty face: clinically, severe asthma attacks look very similar from patient to patient.
Genentech, a member of the Roche Group announced that the FDA has approved the company’s supplemental Biologics License Application for Xolair (omalizumab) prefilled syringe for self-injection across all… read more.
People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new… read more.
Infection with parasitic intestinal worms (helminths) can apparently cause sexually transmitted viral infections to be much more severe elsewhere in the body.
The use of ivermectin for prophylaxis and treatment of covid-19 in Zimbabwe has resulted in a 10-fold reduction in mortality. IMI interviewed Dr Jackie Stone, a family medicine physician in based in Harare, Zimbabwe to find out more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.